PLx Pharma Inc. Reports Second Quarter 2017 Results

Print
| Source: PLX Pharma Inc.

HOUSTON, Aug. 10, 2017 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products, Aspertec™ 325 mg and Aspertec™ 81 mg (referred to together as “Aspertec”™), announced today financial results for the three- and six-month periods ended June 30, 2017.

Highlights of and subsequent to the second quarter of 2017 include:

  • Total net revenue from a federal grant was $375,951, compared to $20,000 for the second quarter of 2016;
     
  • Net loss totaled $2.2 million, or ($0.36) per basic and diluted share, compared to net loss of $1.5 million, or ($0.33) per basic and diluted share, for the second quarter of 2016;
     
  • Entered into a term loan facility with Silicon Valley Bank under which the Company initially borrowed $7.5 million, and will have the right to borrow an additional $7.5 million on or before December 31, 2018, under certain terms. Armentum Partners acted as the Company’s financial advisor on the transaction;
     
  • Completed a registered direct offering of 2,646,091 shares of common stock at an offering price per share of $6.875, as well as a concurrent private placement of warrants to purchase up to an equivalent number of shares of common stock with an exercise price of $7.50 per share, resulting in gross proceeds to the Company of approximately $18.2 million;
     
  • Awarded a $1.9 million grant by the National Cancer Institute (NCI) of the National Institutes of Health (NIH) in support of PLx’s novel formulation of aspirin for chemoprevention of colorectal cancer;
     
  • Appointed Rita O’Connor, a seasoned finance executive with an extensive background in finance, strategic partnering, merger and acquisitions and equity fundraising, as Chief Financial Officer, effective July 1, 2017;
     
  • Strengthened management team adding industry veteran and commercial leader, Michael J. Dillon, as Vice President, Sales and Marketing; and,
     
  • Completed its previously announced merger with Dipexium Pharmaceuticals, Inc., effective as of April 19, 2017.

"We continue to build a strong foundation for the future launch of Aspertec, our liquid-filled aspirin capsule. Aspertec 325mg is FDA-approved for over-the-counter (OTC) distribution, and we are presently preparing to file the 81 mg sNDA,” said Natasha Giordano, President and Chief Executive Officer of PLx Pharma. “We believe this highly differentiated product has the potential to benefit millions of patients at risk for cardiovascular disease and in need of fast-acting, safe, reliable and predictable antiplatelet activity.”

“We are pleased to have strengthened our management team and balance sheet, and look forward to making these differentiated aspirin products available to better meet the needs of patients at risk,” concluded Ms. Giordano.

Second Quarter 2017 Financial Results

Net revenue from a federal grant for the second quarter of 2017 was $375,951, compared to $20,000 for the second quarter of 2016.

Research and development expense increased to $626,296 for the second quarter of 2017, compared to $13,081 for the second quarter of 2016, reflecting the initiation of technology transfer, contract manufacturing activities, and product development activities for Aspertec.

General and administrative expense increased to $4.0 million for the second quarter of 2017 from $1.5 million for the second quarter of 2016, due to increased compensation and outside directors’ fees, public offering costs and higher professional fees, partially offset by lower stock compensation expense.

Net loss for the second quarter of 2017 was $2.2 million, or ($0.36) per basic and diluted share, compared to a net loss of $1.5 million, or ($0.33) per basic and diluted share, for the second quarter of 2016.

Six Months Ended June 30, 2017 and 2016 Financial Results

For the six months ended June 30, 2017, net revenue was $375,951, compared to $20,000 in 2016, this increase is due to a federal grant compared to the prior year.

Research and development expense increased to $754,635 for the six months ended June 30, 2017, compared to $53,041 for the first six months of 2016, reflecting the initiation of technology transfer, contract manufacturing activities, and product development activities for Aspertec.

General and administrative expense increased to $5.2 million for the six months ended June 30, 2017 from $2.3 million for the first six months of 2016, reflecting increased compensation and outside directors’ fees, public offering costs and professional fees, partially offset by lower stock compensation expense.

Net loss for the six months ended June 30, 2017 was $3.7 million, or ($0.69) per basic and diluted share, compared with a net loss of $2.4 million, or ($0.54) per basic and diluted share in the prior year period.

About Aspertec

Aspertec 325 mg is an FDA approved aspirin product being developed to provide high-risk cardiovascular and stroke patients with more reliable and predictable antiplatelet efficacy as compared to enteric coated aspirin, while also reducing the adverse gastric events common in an acute setting. PLx is focused on completing manufacturing scale-up and label finalization for Aspertec 325 mg aspirin dosage form and preparing an sNDA for Aspertec 81 mg maintenance dose form.

About PLx Pharma Inc.

PLx Pharma Inc. is a late-stage specialty pharmaceutical company focused on developing its clinically validated and patent-protected PLxGuard™ delivery system to provide safe and effective aspirin products. The PLxGuard delivery system works by targeting delivery of active pharmaceutical ingredients (API) to various portions of the gastrointestinal (GI) tract. PLx believes this has the potential to improve the absorption of many drugs currently on the market or in development, and to reduce acute GI side effects—including erosions, ulcers and bleeding—associated with aspirin and ibuprofen, and potentially other drugs.

To learn more about PLx Pharma Inc. and its pipeline, please visit www.plxpharma.com.

Forward-Looking Statements

Any statements made in this press release relating to future financial or business performance, conditions, plans, prospects, trends, or strategies and other financial and business matters, including without limitation, the prospects for commercializing or selling any products or drug candidates, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, when or if used in this press release, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and similar expressions and their variants, as they relate to PLx may identify forward-looking statements. PLx cautions that these forward-looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time. Important factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by PLx to secure and maintain relationships with collaborators; risks relating to clinical trials; risks relating to the commercialization, if any, of PLx’s proposed product candidates (such as marketing, regulatory, product liability, supply, competition, and other risks); dependence on the efforts of third parties; dependence on intellectual property and risks that PLx may lack the financial resources and access to capital to fund proposed operations. Further information on the factors and risks that could affect PLx’s business, financial conditions and results of operations are contained in PLx’s filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Other risks and uncertainties are more fully described in PLx’s prospectus supplement filed with the SEC on June 12, 2017, and in other filings that PLx will make going forward. The forward-looking statements represent PLx’s estimate as of the date hereof only, and PLx specifically disclaims any duty or obligation to update forward-looking statements.


PLx Pharma Inc. 
 
  
UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS 
     
 Three Months Ended June 30, Six Months Ended June 30, 
 2017
 2016
 2017
 2016
 
REVENUES:        
Federal grant$375,951  $-  $375,951  $-  
License revenue -   20,000   -   20,000  
TOTAL REVENUES 375,951   20,000   375,951   20,000  
         
OPERATING EXPENSES:        
Research and development 626,296   13,081   754,635   53,041  
General and administrative 4,024,658   1,450,747   5,241,729   2,302,316  
TOTAL OPERATING EXPENSES 4,650,954   1,463,828   5,996,364   2,355,357  
OPERATING LOSS (4,275,003)  (1,443,828)  (5,620,413)  (2,335,357) 
         
OTHER INCOME (EXPENSE)        
Interest income 14,482   309   14,482   378  
Interest expense (642,006)  (24,608)  (723,563)  (34,041) 
Change in fair value of warrant liability 1,746,420   -   1,746,420   -  
TOTAL OTHER INCOME (EXPENSE) 1,118,896   (24,299)  1,037,339   (33,663) 
LOSS BEFORE INCOME TAX BENEFIT (3,156,107)  (1,468,127)  (4,583,074)  (2,369,020) 
Income tax benefit 920,000   -   920,000   -  
NET LOSS$(2,236,107) $(1,468,127) $(3,663,074) $(2,369,020) 
         
Loss per common share - basic and diluted$(0.36) $(0.33) $(0.69) $(0.54) 
         
Weighted average shares of common shares - basic
and diluted
 6,157,970   4,383,433   5,275,603   4,383,433  
         


PLx Pharma Inc.
 
UNAUDITED CONSOLIDATED BALANCE SHEETS
    
 June 30, 2017 December 31,
2016
    
ASSETS   
CURRENT ASSETS   
Cash and cash equivalents$25,079,590  $59,335 
Accounts receivable, net 381,028   5,077 
Inventory, net 394,740   116,726 
Contract manufacturing deposit 657,400   - 
Prepaid expenses 359,293   4,652 
Security deposit 4,064   4,064 
TOTAL CURRENT ASSETS 26,876,115   189,854 
NON-CURRENT ASSETS   
Property and equipment, net 513,986   426,634 
Security deposit - noncurrent 56,630   - 
Intangible assets, net 2,300,000   - 
Goodwill 2,061,022   - 
TOTAL ASSETS$31,807,753  $616,488 
    
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)   
CURRENT LIABILITIES   
Accounts payable and accrued liabilities$476,039  $862,995 
Accrued severance 2,284,000   - 
Accrued interest -   64,781 
Accrued interest - related parties -   30,344 
Convertible notes payable -   1,297,700 
Convertible notes payable - related parties -   480,000 
TOTAL CURRENT LIABILITIES 2,760,039   2,735,820 
NON-CURRENT LIABILITIES   
Deferred revenue 200,000   200,000 
Warrant liability 14,130,126   - 
TOTAL LIABILITIES 17,090,165   2,935,820 
    
    
STOCKHOLDERS' EQUITY (DEFICIT)   
Preferred stock; $0.001 par value; 10,000,000 shares authorized; none issued and outstanding -   - 
Common stock; $0.001 par value; 100,000,000 shares authorized; 8,686,010 and 4,383,433 shares
issued and outstanding at June 30, 2017 and December 31, 2016, respectively
 8,686   4,383 
Additional paid-in capital 70,357,493   49,661,802 
Accumulated deficit (55,648,591)  (51,985,517)
TOTAL STOCKHOLDERS' EQUITY (DEFICIT) 14,717,588   (2,319,332)
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)$31,807,753  $616,488 
    


Contact

Investor Relations:
Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com